A study found that entorhinal hypometabolism detected by FDG-PET scans may be a strong predictor of cognitive decline in patients with preclinical Alzheimer's disease. "Adding low entorhinal FDG as inclusion criterion in preclinical AD trials would significantly increase the power of the trials, researchers wrote in Neurology.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.